- Home
- HUMA vs MAZE Comparison
HUMA vs MAZE Comparison
Compare HUMA & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- MAZE
- Stock Information
- Founded
- HUMA 2004
- MAZE 2018
- Country
- HUMA United States
- MAZE United States
- Employees
- HUMA N/A
- MAZE N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- MAZE
- Sector
- HUMA Health Care
- MAZE
- Exchange
- HUMA Nasdaq
- MAZE NYSE
- Market Cap
- HUMA 367.6M
- MAZE 367.0M
- IPO Year
- HUMA N/A
- MAZE 2025
- Fundamental
- Price
- HUMA $2.47
- MAZE $15.74
- Analyst Decision
- HUMA Strong Buy
- MAZE Strong Buy
- Analyst Count
- HUMA 7
- MAZE 4
- Target Price
- HUMA $13.00
- MAZE $23.50
- AVG Volume (30 Days)
- HUMA 3.4M
- MAZE 127.1K
- Earning Date
- HUMA 08-12-2025
- MAZE 08-14-2025
- Dividend Yield
- HUMA N/A
- MAZE N/A
- EPS Growth
- HUMA N/A
- MAZE N/A
- EPS
- HUMA N/A
- MAZE 0.34
- Revenue
- HUMA $517,000.00
- MAZE $167,500,000.00
- Revenue This Year
- HUMA N/A
- MAZE N/A
- Revenue Next Year
- HUMA $896.45
- MAZE N/A
- P/E Ratio
- HUMA N/A
- MAZE $45.91
- Revenue Growth
- HUMA N/A
- MAZE N/A
- 52 Week Low
- HUMA $1.15
- MAZE $6.71
- 52 Week High
- HUMA $9.79
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- HUMA 55.25
- MAZE N/A
- Support Level
- HUMA $2.25
- MAZE N/A
- Resistance Level
- HUMA $2.80
- MAZE N/A
- Average True Range (ATR)
- HUMA 0.19
- MAZE 0.00
- MACD
- HUMA 0.01
- MAZE 0.00
- Stochastic Oscillator
- HUMA 54.55
- MAZE 0.00
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.